Journals / Turkish Journal of Hematology / 2010 / Cilt: 27 - Sayı: 4

Akut miyeloid lösemili Mısırlı hastalarda çözünür anjiyopoitein -2 ve çözünür Tie-2’nin prognostik değeri

Prognostic value of soluble angiopoietin-2 and soluble Tie-2 in Egyptian patients with acute myeloid leukemia

Pages
282–288
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We evaluated the levels of soluble (s)Ang-2 and sTie-2 in acute myeloid leukemia (AML) patients and investigated the impact of their circulating levels on the overall survival in those patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Angiogenesis plays a critical role in the development and growth of solid tumors and hematologic malignancies.
📊
Key Findings & Data:The system involving angiopoietin-2 [Ang-2] and its receptor Tie-2 appears to play an important role in tumor angiogenesis and in the biology of hematological and non-hematological malignancies.
💡
Conclusion & Impact:We evaluated the levels of soluble (s)Ang-2 and sTie-2 in acute myeloid leukemia (AML) patients and investigated the impact of their circulating levels on the overall survival in those patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: Angiogenesis plays a critical role in the development and growth of solid tumors and hematologic malignancies. The system involving angiopoietin-2 [Ang-2] and its receptor Tie-2 appears to play an important role in tumor angiogenesis and in the biology of hematological and non-hematological malignancies. We evaluated the levels of soluble (s)Ang-2 and sTie-2 in acute myeloid leukemia (AML) patients and investigated the impact of their circulating levels on the overall survival in those patients. METHODS: Ang-2 and Tie-2 were measured in plasma samples from AML patients and controls using enzyme-linked immunosorbent assay (ELISA). RESULTS: The levels of sAng-2 and sTie-2 were significantly higher in AML patients (2382.1±1586.1 pg/ml and 6.74±3.47 ng/ml, respectively) than in controls (649.5±402.6 pg/ml and 2.63±0.57 ng/ml, respectively; p<0.01). AML patients with high levels of sAng-2 and sTie-2 (&#8805;2500 pg/ml and &#8805;8 ng/ml, respectively) had significantly shorter overall survival than those patients with low levels (<2500 pg/ml and <8 ng/ml, respectively). CONCLUSION: The results of our study demonstrated the prognostic significance of circulating sAng-2 and sTie-2 in AML patients. Modulation of the angiopoietin / Tie-2 axis may be a promising approach to improve the outcome in those patients.

Özet

AMAÇ: Anjiyojenez, katı tümörler ve hematolojik hastalıkların gelişimi ve büyümesinde kritik bir rol oynamaktadır. Anjiyopoietin-2 [Ang-2] ve onun reseptörü Tie-2’yi kapsayan sistemin, tümör anjiyojenezinde ve hematolojik ve hematoloji dışı hastalıkların biyolojisinde önemli bir rol oynadığı görülmektedir. AML hastalarında çözünebilen sAng-2 ve sTie-2 düzeyleri değerlendirilmiş olup, bu hastalarda dolaşımdaki düzeylerinin toplam sağkalım üzerindeki etkileri araştırılmıştır. YÖNTEMLER: AMLli hastalar ve kontrollerden alınan plazma örneklerinde, Enzim bağlı immünassay (ELISA) ile Ang-2 ve Tie -2 ölçülmüştür. BULGULAR: AML hastalarında, sAng-2 ve sTie-2 değerleri [sırasıyla 2382.1±1586.1 pg/ml ve 6.74±3.47ng/ml], kontrollere [sırasıyla 649.5±402.6 pg/ml ve 2.63±0.57 ng/ml] kıyasla anlamlı derecede daha yüksekti (p<0.01). Toplam sağkalım değeri,yüksek sAng-2 ve sTie-2 [sırasıyla ≥2500pg/ml ve ≥8ng/ml] değerli AML hastalarında düşük düzeylere [<8ng/ml] kıyasla anlamlı derecede daha kısaydı. SONUÇ: Çalışmada elde edilen sonuçlarda, AML hastalarının dolaşımdaki Ang-2 ve sTie-2 düzeylerinin prognostik anlamlılığı gösterilmiştir. Anjiyopoietin / Tie2 aksisinin modülasyonu, söz konusu hastalarda sonucu geliştirmeye yönelik ümit verici bir yaklaşım olabilir.

🔖

Cite This Article

ATTIA, M. A., HAZZAA, S. M., ESSA, S. A., SELEIM, M. F. (2010). Akut miyeloid lösemili Mısırlı hastalarda çözünür anjiyopoitein -2 ve çözünür Tie-2’nin prognostik değeri. Turkish Journal of Hematology, Cilt: 27 - Sayı: 4, 282–288. https://ajindex.com/articles/413160

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
  2. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4
  3. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000;95:309-13
  4. Padró T, Ruiz S, Bieker R, Bürger H, Steins M, Kienast J, Büchner T, Berdel WE, Mesters RM. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000;95:2637-44
  5. Padró T, Bieker R, Ruiz S, Steins M, Retzlaff S, Bürger H, Büchner T, Kessler T, Herrera F, Kienast J, Müller- Tidow C, Serve H, Berdel WE, Mesters RM. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002;16:1302-10
  6. Santos SC, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 2004;103:3883-9
  7. Padro I, Bieker R, Ruiz S, Steins M, Retzlaff S, Burger H. Over-expression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002;16:1302-10
  8. Fiedler W, Graeven U, Ergün S, Verago S, Kilic N, Stockschläder M, Hossfeld DK. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997;89:1870-5
  9. Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Albitar M. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999;94:3717-21
  10. Maisonpierre PC, Sun C, Jones PF, Bartunkova S, Weigand SJ, Radziejewski C. Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science 1997;277:55
  11. Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM. Chemotactic properties of angiopoietin-1 and -2 ligands for the endothelial-specific receptor tyrosine kinase Tie-2. J Biol Chem 1993;273:18514-21
  12. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997;277:48
  13. Schliemann C, Bieker R, Padro T, Kessler T, Hintelmann H, Buchner T. Expression of angiopoietins and their receptor Tie-2 in the bone marrow of patients with acute myeloid leukemia. Hematologica 2006;91:1203- 11
  14. Quartarone E, Alonci A, Allegra A, Bellomo G, Calabrol L, D`Angelo A. Differenti